Trial
NCT03273153
A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma
Phase IIITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Hoffmann-La Roche
Collaborators
—
Condition
Advanced BRAFV600 Wild-type Melanoma
Intervention
Cobimetinib
Why stopped
This study was terminated due to benefit/risk analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-09-21